Allergan Bolsters Botox Business With Record-Setting Korean Deal
This article was originally published in PharmAsia News
Executive Summary
In the largest licensing deal ever signed by a Korean health care company, Medy-Tox teams up with Allergan for next-generation neurotoxin products that could help Allergan protect its lead as new competitors like J&J look to enter the market.